Patents by Inventor Eric Vangrevelinghe
Eric Vangrevelinghe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251067Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: ApplicationFiled: January 13, 2022Publication date: August 11, 2022Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
-
Patent number: 11254653Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: GrantFiled: May 15, 2020Date of Patent: February 22, 2022Assignee: Novartis AGInventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
-
Patent number: 11208399Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: GrantFiled: May 15, 2020Date of Patent: December 28, 2021Assignee: Novartis AGInventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
-
Patent number: 11203595Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: July 28, 2020Date of Patent: December 21, 2021Assignee: NOVARTIS AGInventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
-
Publication number: 20210188842Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: July 28, 2020Publication date: June 24, 2021Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
-
Publication number: 20200361898Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: ApplicationFiled: May 15, 2020Publication date: November 19, 2020Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
-
Publication number: 20200361899Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: ApplicationFiled: May 15, 2020Publication date: November 19, 2020Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
-
Patent number: 10766894Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: September 21, 2017Date of Patent: September 8, 2020Assignee: NOVARTIS AGInventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
-
Publication number: 20190300522Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: September 21, 2017Publication date: October 3, 2019Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
-
Patent number: 10112907Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: September 21, 2017Date of Patent: October 30, 2018Assignee: NOVARTIS AGInventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
-
Publication number: 20180086716Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
-
Patent number: 8629168Abstract: The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4-c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.Type: GrantFiled: September 13, 2007Date of Patent: January 14, 2014Inventors: Marc Gerspacher, Pascal Furet, Eric Vangrevelinghe
-
Patent number: 8193189Abstract: The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.Type: GrantFiled: June 6, 2008Date of Patent: June 5, 2012Assignee: Novartis AGInventors: Marc Gerspacher, Pascal Furet, Eric Vangrevelinghe, Carole Pissot Sondermann, Christoph Gaul, Philipp Holzer
-
Publication number: 20100168062Abstract: The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R8 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.Type: ApplicationFiled: June 6, 2008Publication date: July 1, 2010Inventors: Marc Gerspacher, Pascal Furet, Eric Vangrevelinghe, Carole Pissot Sondermann, Christoph Gaul, Philipp Holzer
-
Publication number: 20100009978Abstract: The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4-c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.Type: ApplicationFiled: September 13, 2007Publication date: January 14, 2010Inventors: Marc Gerspacher, Pascal Furet, Eric Vangrevelinghe
-
Patent number: 7612054Abstract: The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.Type: GrantFiled: July 23, 2004Date of Patent: November 3, 2009Assignee: Novartis AGInventors: Yves Auberson, Claudia Betschart, Stefanie Flohr, Ralf Glatthar, Oliver Simic, Marina Tintelnot-Blomley, Thomas J. Troxler, Eric Vangrevelinghe, Siem Jacob Veenstra
-
Publication number: 20080194629Abstract: The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-piperidine compound, and/or a method of treatment comprising administering a 3,5-piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.Type: ApplicationFiled: May 2, 2006Publication date: August 14, 2008Inventors: Daniel Kaspar Baeschlin, Werner Breitenstein, Claus Ehrhardt, Juergen Klaus Maibaum, Nils Ostermann, Juerg Zimmermann, Simon Rudisser, Eric Vangrevelinghe, Osamu Irie, Ichiro Umemura, Masaki Suzuki, Muneto Mogi, Takanori Kanazawa, Fumiaki Yokokawa, Atsuko Nihonyanagi
-
Publication number: 20070111991Abstract: The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.Type: ApplicationFiled: July 23, 2004Publication date: May 17, 2007Inventors: Yves Auberson, Claudia Betschart, Stefanie Flohr, Ralf Glatthar, Oliver Simic, Marina Tintelnot-Blomley, Thomas Troxler, Eric Vangrevelinghe, Siem Veenstra